Generic Fibricor Availability
Last updated on Jun 11, 2025.
Fibricor is a brand name of fenofibric acid, approved by the FDA in the following formulation(s):
FIBRICOR (fenofibric acid - tablet;oral)
-
Manufacturer: ATHENA
Approval date: August 14, 2009
Strength(s): 35MG (discontinued) [RLD], 105MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fibricor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods of use of fenofibric acid
Patent 7,569,612
Issued: August 4, 2009
Inventor(s): Arnold; Kristin Anne et al.
Assignee(s): Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
Patent expiration dates:
- August 20, 2027✓
- August 20, 2027
-
Methods of use of fenofibric acid
Patent 7,741,373
Issued: June 22, 2010
Inventor(s): Arnold; Kristin Anne et al.
Assignee(s): Mutual Pharmacuetical Company, Inc. (Philadelphia, PA)Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
Patent expiration dates:
- August 20, 2027✓
- August 20, 2027
-
Methods of use of fenofibric acid
Patent 7,741,374
Issued: June 22, 2010
Inventor(s): Arnold; Kristin Anne et al.
Assignee(s): Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
Patent expiration dates:
- August 20, 2027✓
- August 20, 2027✓
- August 20, 2027
-
Methods of use of fenofibric acid
Patent 7,915,247
Issued: March 29, 2011
Inventor(s): Arnold; Kristin Anne et al.
Assignee(s): Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
Patent expiration dates:
- August 20, 2027✓
- August 20, 2027✓
- August 20, 2027✓
- August 20, 2027
More about Fibricor (fenofibric acid)
- Fibricor consumer information
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: fibric acid derivatives
- En español
Related treatment guides
Related/similar drugs
Crestor
Crestor (rosuvastatin) is used to treat high cholesterol and high triglycerides in the blood ...
Vascepa
Vascepa (icosapent) is used in together with a low-fat and low-cholesterol diet to reduce ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Fish Oil
Fish Oil (omega-3) is used together with diet and exercise to help lower triglyceride levels in the ...
TriCor
Tricor (fenofibrate) helps reduce cholesterol and triglycerides (fatty acids) in the blood ...
Omega-3-Acid Ethyl Esters
Omega-3-Acid Ethyl Esters is used for dietary supplementation, hypertriglyceridemia
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
